TNGX Tango Therapeutics Inc
Price (delayed)
$1.37
Market cap
$148.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.19
Enterprise value
$115.07M
tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million
Highlights
The debt has contracted by 6% YoY and by 3% from the previous quarter
The gross profit rose by 15% year-on-year but it has declined by 3% since the previous quarter
The revenue rose by 15% YoY but it fell by 3% QoQ
The company's net income fell by 28% YoY and by 6% QoQ
The equity has decreased by 21% YoY and by 13% QoQ
Key stats
What are the main financial stats of TNGX
Market
Valuations
Earnings
Shares outstanding
108.11M
Market cap
$148.11M
Enterprise value
$115.07M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
3.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.74
Revenue
$42.07M
Gross profit
$42.07M
Operating income
-$145.6M
Net income
-$130.3M
EBIT
-$130.09M
EBITDA
-$123.85M
Free cash flow
-$132.26M
Per share
Balance sheet
Liquidity
EPS
-$1.19
EPS diluted
-$1.19
Free cash flow per share
-$1.21
Book value per share
$1.86
Revenue per share
$0.39
TBVPS
$2.9
Total assets
$316.49M
Total liabilities
$116.98M
Debt
$36.49M
Equity
$199.52M
Working capital
$228.17M
Debt to equity
0.18
Current ratio
6.98
Quick ratio
6.76
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
-294.4%
Gross margin
100%
Net margin
-309.7%
Operating margin
-346.1%
Return on assets
-35.8%
Return on equity
-55.4%
Return on invested capital
-43%
Return on capital employed
-46.7%
Return on sales
-309.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TNGX stock price
How has the Tango Therapeutics stock price performed over time
Intraday
7.03%
1 week
-11.04%
1 month
-33.82%
1 year
-81.88%
YTD
-55.66%
QTD
0%
Financial performance
How have Tango Therapeutics's revenue and profit performed over time
Revenue
$42.07M
Gross profit
$42.07M
Operating income
-$145.6M
Net income
-$130.3M
Gross margin
100%
Net margin
-309.7%
The company's net income fell by 28% YoY and by 6% QoQ
Tango Therapeutics's operating income has decreased by 28% YoY and by 4.2% QoQ
The gross profit rose by 15% year-on-year but it has declined by 3% since the previous quarter
The revenue rose by 15% YoY but it fell by 3% QoQ
Growth
What is Tango Therapeutics's growth rate over time
Valuation
What is Tango Therapeutics stock price valuation
P/E
N/A
P/B
0.74
P/S
3.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.74
Tango Therapeutics's EPS has decreased by 10% YoY and by 2.6% QoQ
The stock's P/B is 85% less than its 5-year quarterly average of 4.7 and 77% less than its last 4 quarters average of 3.0
The equity has decreased by 21% YoY and by 13% QoQ
TNGX's price to sales (P/S) is 85% lower than its 5-year quarterly average of 22.7 and 82% lower than its last 4 quarters average of 18.1
The revenue rose by 15% YoY but it fell by 3% QoQ
Efficiency
How efficient is Tango Therapeutics business performance
The ROA is down by 42% year-on-year and by 12% since the previous quarter
TNGX's ROIC is down by 41% YoY and by 13% from the previous quarter
The ROE is down by 32% year-on-year and by 12% since the previous quarter
Tango Therapeutics's return on sales has decreased by 11% YoY and by 9% QoQ
Dividends
What is TNGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TNGX.
Financial health
How did Tango Therapeutics financials performed over time
The total assets is 171% more than the total liabilities
The total liabilities is down by 22% year-on-year and by 5% since the previous quarter
The total assets has contracted by 21% YoY and by 10% from the previous quarter
The debt is 82% less than the equity
The equity has decreased by 21% YoY and by 13% QoQ
The debt to equity has grown by 20% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.